Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

Romain Fournier

Chief Editor
Having worked in the British, French and Swiss financial press, Romain is able to report on local and international issues, as comfortable in French as in the language of Shakespeare, Romain Fournier leads the editorial team at Marketscreener. Fine connoisseur of the English-speaking markets, Romain delivers an editorial every day on US and UK markets.

Analyst recommendations: Apple, FedEx, Intellia Therapeutics, Reckitt Benckiser, XPO Logistics...

06/30/2021 | 06:12am EST

After encouraging data on transthyretin amyloidosis therapy, Oppenheimer significantly raised Intellia Therapeutics' price target. Menawhile, CMS Energy saw its PT cut by RBC following the sale of Enerbank USA unit to regions. Apple and Fedex are also included in today's selection of analyst recommendations.



  • Apple: UBS reiterates its Buy rating. The target price is still set at USD 155.
  • BlackRock TCP Capital : Oppenheimer assumes coverage on stock with outperform rating, $15 pt
  • Cairn Energy: Berenberg upgraded from buy to hold, targeting GBp 170.
  • CMS Energy : price target from RBC cut to $64 from $66, sector perform kept
  • FedEx : Argus raises pt to $330 from $305, maintains buy rating
  • Hibbett : Williams Research raises price target to $147 from $110, keeps buy rating
  • Intellia Therapeutics : Oppenheimer lifts pt to $125 from $73, maintains perform rating
  • Jefferies Financial : Oppenheimer adjusts pt to $40 from $37, maintains outperform rating
  • Johnson Matthey: AlphaValue remains Buy with a price target raised from GBp 3355 to GBp 3526.
  • Orchard Therapeutics : Wedbush adjusts price target to $13 from $15, maintains outperform rating
  • Reckitt Benckiser: JP Morgan reiterates Buy rating. The target price remains unchanged at GBp 9000.
  • Royal Dutch Shell: Citigroup upgrades from sell to neutral with a target of GBp 1,450.
  • Taylor Wimpey: Liberum remains Buy with target price raised to GBP 195 from GBP 185.
  • The Boeing Company: Goldman Sachs keeps Buy rating. The target price is unchanged and still at USD 307.
  • Ultragenyx Pharmaceutical : BofA upgrades to buy rating from neutral, maintains $162 price objective
  • Workspace: RBC upgrades from sector perform to outperform with a target of GBP 1050.
  • XPO Logistics : JPMorgan adjusts price target to $190 from $160, maintains overweight rating

ę MarketScreener.com 2021